A big congratulations to Trang Tran on being awarded the MPCCC precision medicine scholarship! Trang is currently doing her PhD in the Hormone Cancer Therapeutics laboratory at the Hudson Institute, headed by Dr. Simon Chu. “My interests lie in understanding the molecular mechanisms involved in the pathogenesis of ovarian granulosa [...]
Clinicians and patients across MPCCC partner health services have enthusiastically responded to the MPCCC Precision Oncology Program in 2020, and this month the program has reached a new milestone: 100 patients have been referred for molecular tumour profiling. The MPCCC’s partnership with Omico, a national research program based in Sydney, has [...]
Molecular profiling of solid tumours is now more accessible for people with cancer, who are being treated across south-eastern Victoria, following the establishment of the MPCCC Precision Oncology Program. Over 80 patients with rare, therapy-resistant or advanced stage cancers have already been referred for screening through the MPCCC across a range of tumour [...]
This month, the ovarian cancer research program at the Hudson Institute of Medical Research, in a collaboration with Monash Health, was awarded $2.2 million from the Australian Government’s Medical Research Future Fund (MRFF). The announcement was made on World Ovarian Cancer Day, Friday 8th May 2020. The MPCCC, in partnership [...]
A new MPCCC partnership with Monash University’s Biomedicine Discovery Institute (Monash BDI) will investigate whether innovative research technologies, including multi-omic and organoid profiling, can improve the future accuracy of precision oncology. Cancer patients referred to the MPCCC Molecular Screening and Therapeutics Program are now offered the opportunity to contribute to future [...]
Cancer patients are likely to benefit from more targeted treatments following work that has increased the number of identifiable cancer genome signatures to 97. The result of a landmark international study published in Nature this month, identification of the new genome signatures is attributed to the work of over 700 [...]
Cancer patients treated in Victoria will benefit from more affordable access to molecular tumour profiling, following a new collaboration between the Australian Genomic Cancer Medicine Centre (AGCMC) and the MPCCC’s Precision Oncology Program. The AGCMC, a $50million federally funded national initiative led by Professor David Thomas at the Garvan Institute [...]
A next-generation sequencing instrument, the NovaSeq6000, will build genomic research capacity for MPCCC partners and increase the speed and affordability of comprehensive tumour genome profiling for cancer patients. The new NovaSeq6000, based at Alfred Health, can simultaneously sequence 24-48 human genomes in 48 hours, depending on run settings. Its design [...]
A non-invasive blood test could help doctors to diagnose cancer and monitor patient responses to treatment, based on the outcomes of MPCCC research project, The PRECISE Assay (personalised medicine for cancer patients using next-generation sequencing). “We have designed a gene sequencing test that can inform doctors of the state and [...]
The MPCCC Precision Oncology Program welcomed two eminent speakers in August and September 2019 to present at Precision Oncology Seminars. These seminars brought together researchers and clinicians from across MPCCC partners to hear how precision oncology techniques can enable effective individualised treatments for rare and aggressive cancers. Dr Richard Tothill, Head [...]
